TY - JOUR
T1 - Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma
T2 - A New Approaches to Brain Tumor Therapy CNS Consortium Trial
AU - Olivi, Alessandro
AU - Grossman, Stuart A.
AU - Tatter, Stephen
AU - Barker, Fred
AU - Judy, Kevin
AU - Olsen, Jeffrey
AU - Bruce, Jeffrey
AU - Hilt, Dana
AU - Fisher, Joy
AU - Piantadosi, Steve
PY - 2003/5/1
Y1 - 2003/5/1
N2 - Purpose: This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU. Patients and Methods: Forty-four adults underwent tumor debulking and polymer placement. Six patients per dose level were studied using polymers with 6.5%, 10%, 14.5%, 20%, and 28% BCNU by weight. Toxicities were assessed 1 month after implantation by a safety monitoring committee to determine whether subsequent escalations should occur. Nine additional patients were studied at the MTD to confirm safety. BCNU blood levels were obtained before and after polymer implantation. Results: No dose-limiting toxicities were identified at the 6.5%, 10%, or 14.5% dose levels, although difficulties with wound healing, seizures, and brain edema were noted. At the 20% dose, these effects seemed more prominent, and six additional patients were treated at this dose and tolerated treatment well. Three of four patients receiving the 28% polymers developed severe brain edema and seizures, and accrual to this cohort was stopped. Nine additional patients received 20% polymer, confirming this as the MTD. Maximum BCNU plasma concentrations with the 20% loaded polymers were 27 ng/mL Overall median survival was 251 days. Conclusion: The MTD of BCNU delivered in polymer to the surgical cavity is 20%. This polymer provides five times more BCNU than standard commercially available BCNU polymers and results in minimal systemic BCNU exposure. Additional studies are needed to establish the efficacy of high-dose BCNU polymers.
AB - Purpose: This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU. Patients and Methods: Forty-four adults underwent tumor debulking and polymer placement. Six patients per dose level were studied using polymers with 6.5%, 10%, 14.5%, 20%, and 28% BCNU by weight. Toxicities were assessed 1 month after implantation by a safety monitoring committee to determine whether subsequent escalations should occur. Nine additional patients were studied at the MTD to confirm safety. BCNU blood levels were obtained before and after polymer implantation. Results: No dose-limiting toxicities were identified at the 6.5%, 10%, or 14.5% dose levels, although difficulties with wound healing, seizures, and brain edema were noted. At the 20% dose, these effects seemed more prominent, and six additional patients were treated at this dose and tolerated treatment well. Three of four patients receiving the 28% polymers developed severe brain edema and seizures, and accrual to this cohort was stopped. Nine additional patients received 20% polymer, confirming this as the MTD. Maximum BCNU plasma concentrations with the 20% loaded polymers were 27 ng/mL Overall median survival was 251 days. Conclusion: The MTD of BCNU delivered in polymer to the surgical cavity is 20%. This polymer provides five times more BCNU than standard commercially available BCNU polymers and results in minimal systemic BCNU exposure. Additional studies are needed to establish the efficacy of high-dose BCNU polymers.
UR - http://www.scopus.com/inward/record.url?scp=0038473995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038473995&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.09.041
DO - 10.1200/JCO.2003.09.041
M3 - Article
C2 - 12721262
AN - SCOPUS:0038473995
SN - 0732-183X
VL - 21
SP - 1845
EP - 1849
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -